Cytek Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Cytek Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at .FREMONT, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 36th Annual Healthcare Conference in New York, NY.
加利福尼亞州弗裏蒙特，2024年11月20日（環球新聞社）- 麥克生物科技公司（納斯達克股票代碼：CTKB），一家領先的細胞分析解決方案公司，今天宣佈公司將參加即將舉行的第36屆派傑投資健康醫療大會，地點爲紐約，紐約。
Cytek management is scheduled to participate in a fireside chat on Tuesday, December 3, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com.
麥克管理團隊定於2024年12月3日星期二下午4:30（東部時間1:30（太平洋時間）參加爐邊聊天。有興趣的各方可以在公司網站的「投資者」欄目上查看演示的現場直播和存檔網絡廣播，網址爲：investors.cytekbio.com。
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at .
納斯達克:CTKB是引領細胞分析解決方案的公司，通過提供高分辨率、高內容和高靈敏度的細胞分析工具，推動下一代細胞分析工具。利用其擁有專利的全光譜分析（FSP）技術，Cytek的新穎方法利用熒光信號全譜中的信息力量，實現更高水平的多重化，具有精準性和靈敏度。Cytek的FSP平台包括其核心儀器Cytek Aurora和Northern Lights系統；其分選機Cytek Aurora CS；Cytek Orion試劑混合系統；增強小顆粒（ESP）檢測技術；Amnis和Guava品牌下的流式細胞儀和成像產品；以及試劑、軟件和服務，爲客戶提供全面和集成的解決方案套件。Cytek總部位於加利福尼亞州弗裏蒙特，分佈全球各地的辦公室和分銷渠道。有關公司及其產品的更多信息，請訪問。
Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).
Cytek的產品僅供研究使用，不用於診斷程序（除了中國和歐盟的Cytek Northern Lights-CLC系統和某些試劑可用於臨床使用）
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Enhanced Small Particle, ESP, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
Cytek、Full Spectrum Profiling、FSP、Cytek Aurora、Northern Lights、Cytek Orion、Enhanced Small Particle、ESP、Amnis和Guava是Cytek Biosciences, Inc.的商標。
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
除了向證券交易委員會（SEC）提交文件、新聞稿、公開電話會議和網絡直播外，Cytek還將其網站（）、LinkedIn頁面和X（前稱Twitter）帳戶用作分發有關公司、產品、擬定的財務和其他公告、參加即將舉行的投資者和行業會議以及其他事項的信息渠道。這些信息可能被視爲重要信息，Cytek可能使用這些渠道以遵守根據FD法規的披露義務。因此，投資者應該監控Cytek的網站、LinkedIn頁面和X帳戶，以及關注其證券交易委員會提交的文件、新聞發佈、公開電話會議和網絡直播。
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
媒體聯繫：
Stephanie Olsen
Lages＆Associates
（949）453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
投資者聯繫人：
Paul Goodson
投資者關係主管
Cytek Biosciences
pgoodson@cytekbio.com
譯文內容由第三人軟體翻譯。
